EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Melatonin increases Olaparib sensitivity and suppresses cancer-associated fibroblast infiltration via suppressing the LAMB3-CXCL2 axis in TNBC

Yi-Wen Lai, Zei-Wei Liu, Mei-Hsiang Lin, Ching-Chieh Yang, Cheng-Ying Chu, Chu-Hung Chung, Cheng-Wei Lin

Pharmacological Research · 2024

DOI: 10.1016/j.phrs.2024.107429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacological Research, 2024. Verfasst von Yi-Wen Lai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Biochemistry and Molecular Cell…. Hauptthemen laut MEDLINE: Phthalazines, Melatonin, Piperazines, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, Chi Mei Medical Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is the most malignant breast cancer subtype, characterized with high aggressiveness and a high recurrence rate. Olaparib is the first US Food and Drug Administration-approved poly(ADP ribose) polymerase (PARP) inhibitor (PARPi) to treat breast cancer patients with a germline BRCA1 or BRCA2 mutation. However, resistance to Olaparib treatment restricts the therapeutic effects, and thus novel therapeutics are urgently required. In the present study, we identified that the combination of melatonin and Olaparib synergistically enhanced the sensitivity of TNBC cells. Moreover, melatonin exerted promising antitumor activities in Olaparib-resistant cells, implying the potential for its clinical application. An RNA-sequencing analysis revealed that melatonin treatment downregulated laminin subunit beta 3 (LAMB3) expression. Genetic ablation of LAMB3 significantly increased Olaparib sensitivity, and subsequently suppressed proliferation, epithelial-to-mesenchymal transition (EMT)-related gene expressions, and aggressiveness of breast cancer cells. Accordingly, LAMB3 expression was positively correlated with C-X-C motif chemokine ligand 2 (CXCL2), and they collaboratively promoted cancer-associated fibroblast (CAF) infiltration. An in vivo study demonstrated that combined treatment with melatonin and Olaparib showed enhanced inhibitory efficacy against tumor growth, LAMB3 expression, CXCL2 levels, and CAF infiltration compared to single treatment groups, and combined treatment with melatonin and Olaparib significantly ameliorated the immunosuppressive tumor microenvironment. These findings illustrate a promising therapeutic strategy using melatonin to overcome Olaparib resistance and activate antitumor immunity via attenuating the LAMB3-CXCL2 axis in breast cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhthalazinesMelatoninPiperazinesTriple Negative Breast NeoplasmsCancer-Associated FibroblastsAnimalsFemaleHumansCell Line, TumorChemokine CXCL2Antineoplastic AgentsDrug Resistance, NeoplasmMiceMice, NudeMice, Inbred BALB CDrug Synergism

Stichwörter der Autor:innen

CXCL2Cancer-associated fibroblastsImmune microenvironmentLAMB3MelatoninOlaparibTriple-negative breast cancer

Substanzen

PhthalazinesolaparibMelatoninPiperazinesChemokine CXCL2Antineoplastic Agents

Autor:innen und Institutionen

  • Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, Taipei, Taiwan; Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical Univ…
  • Department of Biochemistry and Molecular Cell Biology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • Department of Radiation Oncology, Chi Mei Medical Center, Tainan, Taiwan; Department of Pharmacy, Chia-Nan University of Pharmacy and Science, Tainan, Taiwan; School of Medicine, College of Medicine, National Sun Yat-se…
  • CRISPR Gene Targeting Core Lab, Taipei Medical University, Taipei, Taiwan.

Förderung

  • Ministry of Science and Technology, Taiwan
  • Chi Mei Medical Center

Zitieren

APA

Lai, Y. W., Liu, Z. W., Lin, M. H., Yang, C. C., Chu, C. Y., Chung, C. H., & Lin, C. W. (2024). Melatonin increases Olaparib sensitivity and suppresses cancer-associated fibroblast infiltration via suppressing the LAMB3-CXCL2 axis in TNBC. Pharmacological Research. https://doi.org/10.1016/j.phrs.2024.107429

Vancouver

Lai YW, Liu ZW, Lin MH, Yang CC, Chu CY, Chung CH, et al. Melatonin increases Olaparib sensitivity and suppresses cancer-associated fibroblast infiltration via suppressing the LAMB3-CXCL2 axis in TNBC. Pharmacological Research. 2024. doi:10.1016/j.phrs.2024.107429

BibTeX
@article{Lai2024,
  author = {Lai, Yi-Wen and Liu, Zei-Wei and Lin, Mei-Hsiang and Yang, Ching-Chieh and Chu, Cheng-Ying and Chung, Chu-Hung and Lin, Cheng-Wei},
  title = {Melatonin increases Olaparib sensitivity and suppresses cancer-associated fibroblast infiltration via suppressing the LAMB3-CXCL2 axis in TNBC},
  journal = {Pharmacological Research},
  year = {2024},
  doi = {10.1016/j.phrs.2024.107429}
}
Kostenlos starten →